• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Fat but Fit: Fact or Myth?

News
Slideshow

No metabolic derangement, insulin sensitivity preserved; fat on the macrometabolic level can look fit. Now, let's look deeper. 

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
FDA Clears Omnipod 5 Algorithm Updates, Adding 100 mg/dL Target Glucose Option / image credit ©Tada Images/stock.adobe.com

FDA Clears Omnipod 5 Algorithm Updates, Adding 100 mg/dL Target Glucose Option

Sydney Jennings
December 4th 2025
Article

Insulet enhances the Omnipod® 5 system with new glucose targets and algorithms, improving insulin delivery for diabetes management.

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

Sydney Jennings
November 13th 2025
Podcast

Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.

Obesity Linked to Faster Alzheimer’s Disease Progression in Longitudinal Blood Biomarker Analysis / image credit Cyrus Raji, MD, PhD Courtesy of RSNA

Obesity Linked to Faster Alzheimer Disease Progression in Longitudinal Blood Biomarker Analysis

Grace Halsey
December 2nd 2025
Article

Biomarker trajectories over 5 years in study participants with AD show steeper rises in pTau217, NfL, and amyloid burden among those with obesity, highlighting risk factor relevance.

Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes

Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes

Sydney Jennings
September 24th 2025
Podcast

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

Evolocumab Associated with Lower Long-term Cardiovascular Event Risk in Real-world Study of More Than 110 000 Patients

Evolocumab Associated with Lower Long-term Cardiovascular Event Risk in Real-world Study of More Than 110 000 Patients

Sydney Jennings
December 1st 2025
Article

New data reveals evolocumab significantly reduces long-term major cardiovascular event risks in ASCVD patients, enhancing treatment strategies for better outcomes.

Novo Nordisk Seeks FDA Approval for Higher-Dose Semaglutide 7.2 mg for Chronic Weight Management

Novo Nordisk Seeks FDA Approval for Higher-Dose Semaglutide 7.2 mg for Chronic Weight Management

Sydney Jennings
November 26th 2025
Article

Novo Nordisk submits an FDA application for semaglutide 7.2 mg for chronic weight management, supported by STEP UP trial data showing greater weight loss.

© 2025 MJH Life Sciences

All rights reserved.